Alpha-1 Adrenergic-Antagonist Use Increases the Risk of Sleep Apnea: A Nationwide Population-Based Cohort Study

Abstract

Study Objectives: Decreased upper-airway muscle responsiveness is one of the major phenotypes of obstructive sleep apnea. Use of α1-adrenergic antagonists is correlated with decreased muscle responsiveness in animal studies, but this association has not yet been demonstrated in humans. This study examined whether use of α1-adrenergic antagonists is an independent risk factor for sleep apnea in humans. Methods: Data for this retrospective cohort study were obtained from the National Health Insurance Research Database from Taiwan. Between 2000 and 2012, 25,466 patients with hypertension and 18,930 patients without hypertension were enrolled. These groups were divided into α1-adrenergic antagonist users and nonusers, matched by age, sex, and index year. Individuals were monitored for diagnosis of sleep apnea until 2013. Results: After adjusting for propensity score and potential confounders, including age, geographic location, enrollee category, income, urbanization level, comorbidities, and medication, the adjusted hazard ratios (HRs) for development of sleep apnea with α1-adrenergic antagonist use were 2.38 (95% confidence interval [CI] 1.82-3.10) and 2.82 (95% CI 1.79-4.44) in the hypertension and nonhypertension groups, respectively. Similarly, the adjusted HRs for development of severe sleep apnea with α1-adrenergic antagonist use were 2.74 (95% CI 1.78-4.22) and 4.23 (95% CI 1.57-11.40) in hypertension and nonhypertension patient groups, respectively. The interaction between α1-adrenergic-antagonist user and patients with hypertension was tested using multivariable Cox regression. The results showed that there are positive additive interactions for developing sleep apnea and severe sleep apnea, respectively. Conclusions: Our study suggests that patients with hypertension using α1-adrenergic antagonists have a higher risk of sleep apnea. Routine sleep apnea screening would be beneficial for patients with hypertension who take α1-adrenergic antagonists.

The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea

“…Theoretically, their blockage could lead to increased collapsibility resulting higher AHI. In line with this, alpha-1 adrenergic antagonists use was associated with increased AHI in a population-based study [15]. However, in our study we did not find a significant relationship between the AHI and beta-blocker use, the only exception was carvedilol in the Hungarian subgroup.…”

Risk factors and clinical prediction formula for the evaluation of obstructive sleep apnea in Asian adults

“…Specifically, OSA is known to affect uncontrolled HTN; however, it remains unclear how HTN affects the incidence or severity of OSA, as well as the risk factors for OSA. Some studies have reported HTN as a risk factor or predictor for OSA [30][31][32]; with certain medications for controlling HTN affecting OSA severity [33]. Further, the similarity of risk factors between HTN and OSA, including age, male sex, and obesity, may have influenced the analysis of HTN as a risk factor of OSA.…”

The Many Faces of Sleep Disorders in Post-Traumatic Stress Disorder: An Update on Clinical Features and Treatment

“…Recent meta-analyses revealed that prazosin is effective in the treatment of post-traumatic nightmares, whereas its effects on sleep quality and PTSD symptoms in general are less favorable [125, 126]. Interestingly, a recent study has shown that prazosin was associated with an increased risk of OSAS [127], finding that may help to explain why some patients do not experience an increase in their sleep quality [128]. Prazosin is not available in some European countries.…”